University Health Network, Toronto

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, University Health Network, Toronto sits in the top decile of US sponsors by registered trial count (#668 of 15,742 sponsors by registered trial count).

23 total trials 6 currently recruiting 14 completed early-phase tilt top decile by trial count

University Health Network, Toronto: 23 sponsored US clinical trials, 6 recruiting.

University Health Network, Toronto sponsors 23 registered US clinical trials on ClinicalTrials.gov, 6 of them currently recruiting, and 14 completed. 1 of these trials are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Organ Preservation, with 1 trials.

Top-decile sponsor footprint

University Health Network, Toronto ranks in the top decile of sponsors by registered trial count (#668 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 58/100

14 of 16 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (87.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

23 total, page 1 of 1

RECRUITING

EXtubation Related Complications - the EXTUBE Study (EXTUBE)

NCT06442930

RECRUITING Phase 4

The STOP-MED CTRCD Trial

NCT06183437

RECRUITING Phase 2

MR-Adaptive Radiation Therapy for Anal Cancer With EScalated-Treatment in a Risk-Optimized Approach

NCT06050707

RECRUITING NA

Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)

NCT05592938

RECRUITING NA

Platform of Randomized Adaptive Clinical Trials in Critical Illness

NCT05440851

RECRUITING NA

FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery

NCT04016389

ACTIVE NOT RECRUITING NA

10°C vs 4°C Lung Preservation RCT

NCT05898776

COMPLETED

Swallowing Impairment After COVID-19 Infection

NCT04537650

COMPLETED Phase 2

Pancreatic Adenocarcinoma Signature Stratification for Treatment

NCT04469556

TERMINATED NA

Tongue Pressure Resistance Training for Swallowing Impairment Post-Stroke

NCT03969095

COMPLETED NA

PRO-ACTIVE: Prophylactic Swallow Intervention for Patients Receiving Radiotherapy for Head and Neck Cancer

NCT03455608

COMPLETED

Physiological Flow of Liquids Used in Dysphagia Management (Neuro)

NCT03192358

COMPLETED Phase 1

Safety and Tolerability of Perampanel in Cervical Dystonia

NCT02131467

COMPLETED Phase 2

12-Week Study Evaluating the Efficacy, Safety, and Tolerability of Adjunctive Infliximab for Bipolar I/II Depression

NCT02363738

COMPLETED Phase 1

A Study of CFI-400945 Fumarate in Patients With Advanced Cancer

NCT01954316

TERMINATED Phase 1

A Trial of ASP7487 (OSI-906) in Combination With Bortezomib for the Treatment of Relapsed Multiple Myeloma

NCT01672736

COMPLETED Phase 1

Safety Study Evaluating Intravenous Infusions of Tigecycline to Treat Acute Myeloid Leukemia

NCT01332786

COMPLETED

Colorectal Cancer Screening for Cancer Survivors

NCT00982059

COMPLETED NA

Development of a Web-Based Course to Maintain Skills in Nurses Trained to Screen for Dysphagia

NCT00570557

COMPLETED

Effects of Exemestane on Bone Strength

NCT01144468

COMPLETED Phase 2

Bortezomib in Treating Patients With Advanced or Metastatic Transitional Cell Cancer of the Bladder, Renal Pelvis, or Ureter

NCT00066352

COMPLETED Phase 2

Tipifarnib in Treating Patients With Recurrent Bladder Cancer

NCT00047216

COMPLETED Phase 2

Imatinib Mesylate in Treating Patients With Salivary Gland Cancer

NCT00045669

What is open in the University Health Network, Toronto pipeline

6 recruiting of 23 indexed (26% open); 14 completed (61%).

Phase mix: 1 late (III/IV) vs 10 early (I/II) (early-phase heavy).

Top condition: Organ Preservation (1 trial), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University Health Network, Toronto: open-pipeline peers nationwide

Peers matched on 23 registered trials and 26% open enrollment, not the therapeutic-area sidebar.

University Health Network, Toronto sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0100200300400500 0%10%20%30% Total trials Recruiting share University Health Network, TorontoAMAG PharmaceuticalsAtriCureCara TherapeuticsCraig L Slingluff, JrShirley Ryan AbilityLabSyracuse UniversityRutgers, The State University of New JerseyHackensack Meridian Health
University Health Network, Toronto sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University Health Network, Toronto sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 23 trials (± recruiting share)

Sponsors near 26% open enrollment (± trial volume)

What to do with this University Health Network, Toronto page

23 registered trials is a research-attention snapshot, not an endorsement of University Health Network, Toronto or any single study.

  • 6 of University Health Network, Toronto's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Organ Preservation is the condition University Health Network, Toronto studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Organ Preservation trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University Health Network, Toronto pipeline card: 23 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.